Please try another search
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Name | Age | Since | Title |
---|---|---|---|
Takumi Kawabe | 64 | 2000 | Co-Founder, CEO, President & Representative Director |
Makoto Katozumi | 58 | 2000 | CFO, GM of Corporate Planning Office & Director |
Daniel Douglas Von Hoff | 75 | - | Chairman of Scientific Advisory Board |
Akira Shirakawa | 68 | 2006 | Independent Outside Director |
Toshiyuki Hibino | 47 | 2020 | COO, GM of Research & Development and Director |
Toshio Furuta | 61 | 2007 | Independent Outside Director |
Kazuyoshi Sakamoto | 60 | 2010 | Manager of Management & Director |
Yasuyuki Komiyama | 64 | 2016 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review